Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

Peer Review reports

Original Submission
14 Jun 2017	Submitted	Original manuscript
5 Sep 2017	Reviewed	Reviewer Report - Peyman Eshghi
2 Jan 2018	Reviewed	Reviewer Report - Marisa Santos
5 Feb 2018	Author responded	Author comments - Valentina Lorenzoni
Resubmission - Version 2
5 Feb 2018	Submitted	Manuscript version 2
7 Feb 2018	Reviewed	Reviewer Report - Marisa Santos
5 Jun 2018	Author responded	Author comments - Valentina Lorenzoni
Resubmission - Version 3
5 Jun 2018	Submitted	Manuscript version 3
Publishing
15 Jul 2018	Editorially accepted
2 Aug 2018	Article published	10.1186/s12913-018-3398-x

Back to article page